The Tumor Lysis Syndrome
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
The tumor lysis syndrome is the most common disease-related emergency in children and adults with hematologic cancers. This review summarizes current strategies for risk assessment, prophylaxis, and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An important consideration with respect to safety in patients that may have a compromised immune system is that engineered bacterial products are likely to engage both innate and adaptive immunity in the event of release of the organism into the body following tumor lysis75, triggering inflammatory responses.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802639 · Cited by 1,759
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Self-citationTumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0177 · Cited by 792
Self-citationCairo, M. S., Coiffier, B., Reiter, A., Younes, A., & Panel, O. B. O. T. T. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08143.x · Cited by 570
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
Cairo, M. S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C. R., Michon, J., Weston, C., Perkins, S. L., Raphael, M., McCarthy, K., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036665 · Cited by 363
Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.697 · Cited by 361
Self-citationOral Phosphate Binders in Patients with Kidney Failure
Tonelli, M., Pannu, N., & Manns, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912522 · Cited by 339
Cited by
Items 301–400 of 1,000
Monitoring and Management of Toxicities of Novel B Cell Signaling Agents
Rhodes, J. M., Mato, A. R., & Sharman, J. P. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0694-x · Cited by 15
Kozani, P. S., & Shabani, S. (2021) · Trends in Medical Sciences · doi:10.5812/tms.116301 · Cited by 15
“Suchmetaboliccontentscaneventuallycausemedicalcon-ditions such as hyperphosphatemia, hyperuricemia, and hyperkalemia (60).”
Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer
Hayes, S. M., Wiese, C., & Schneidewend, R. (2021) · Case Reports in Oncology · doi:10.1159/000519566 · Cited by 15
Bozorgi, A., Bozorgi, M., & Khazaei, M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00700-w · Cited by 15
“This imbalanced state may lead to tumor lysis syndrome (TRS), manifested by hyperuricemia, hyperphosphatemia, hyperkalemia and hypocalcemia [186].”
BackgroundSpontaneous tumour lysis syndrome in small cell lung cancer: a rare phenomenon
Dhakal, P., Rai, M. P., Thrasher, M., & Sharma, M. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-224512 · Cited by 15
A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
Fa’ak, F., Vanegas, D., & Osei, K. M. (2019) · American Journal of Case Reports · doi:10.12659/ajcr.915351 · Cited by 15
“The risk is higher in the presence of a large tumor burden, high cell proliferation rate, chemosensitive malignancy, and preexisting hyperuricemia, hyperphosphatemia, or kidney injury [15].”
BackgroundSanagawa, A., Hotta, Y., Kondo, M., Nishikawa, R., Tohkin, M., & Kimura, K. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000862 · Cited by 15
DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns
Zheng, K., Kros, J. M., Li, J., & Zheng, P. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.005 · Cited by 15
Launay, M., Guitton, J., Balluet, R., Carla-Moreau, A., Phelip, J., Tholance, Y., & Gonzalo, P. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.073 · Cited by 15
Elinoff, J. M., Salit, R. B., & Ackerman, H. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1106641 · Cited by 15
Hanson, S., Grimes, D. R., Taylor‐King, J. P., Bauer, B., Warman, P. I., Frankenstein, Z., Kaznatcheev, A., Bonassar, M. J., Cannataro, V. L., Motawe, Z. Y., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/049908 · Cited by 15
“While killing cancer cells is precisely the intended outcome of these therapies, an extremely high rate of cell death within the body, regardless of cell type, can have severe consequences causing, for example seizures, renal failure, arrhythmias, and death [6].”
BackgroundValtis, Y. K., Nemirovsky, D., Derkach, A., Sharan, S., Kabel, C. C., Ortíz, R., Thompson, M. C., Roeker, L. E., & Geyer, M. B. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013927 · Cited by 14
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report
Kaur, V., & Swami, A. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216637218 · Cited by 14
“Usual indications for initiation of renal replacement therapy are refractory hyperkalemia and hyperphosphatemia.(16,17) In conclusion, this patient developed clinical TLS with institution of single agent ibrutinib for his refractory MCL.”
BackgroundKhazoom, F., L’Écuyer, S., Kim, G., Gagné, M.-A., Bouchard, C., Rose, C. F., Rousseau, G., & Charbonney, E. (2020) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000002868 · Cited by 14
Xiao, Y., Xiao, L., Zhang, Y., Xu, X., Guan, X., Guo, Y., Shen, Y., Lei, X., Dou, Y., & Yu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1337295 · Cited by 14
“…labyrinthine for hyperuricemia, and renal replacement therapy may be required in severe cases (14) Clinical observations suggest that TLS tends to occur in highly proliferative malignancies with heavy tumor loads or sensitive responses to initial therapy, such as Burkitt ’ s lymphoma and ALL (15).”
BackgroundUpdate on the prevention and treatment of tumor lysis syndrome
Sury, K. (2019) · Journal of Onco-Nephrology · doi:10.1177/2399369319837212 · Cited by 14
Islam, P., & Mato, A. R. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00584-3 · Cited by 14
Camarata, M. A., Davies, R., Copley, S., & Blagden, S. P. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-009532 · Cited by 14
Goyal, H., Sawhney, H., Bekara, S., & Singla, U. (2014) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-014-9632-9 · Cited by 14
Jiao, D., Liu, Y., Lu, X., Pan, Q., Zheng, J., Liu, B., Liu, Y., Wang, Y., & Fu, N. (2012) · Allergy · doi:10.1111/all.12089 · Cited by 14
“Particularly, cell components could act as antigens from dead tumour cells following antibody or chemical therapy, such as that observed in tumour lysis syndrome (30).”
BackgroundTumor lysis syndrome and metastatic melanoma
Meeks, M. W., Hammami, M. B., Robbins, K. J., Cheng, K. L., & Lionberger, J. M. (2016) · Medical Oncology · doi:10.1007/s12032-016-0854-5 · Cited by 14
Raru, Y., Abouzid, M., Parsons, J., & Zeid, F. M. (2018) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2018.12.011 · Cited by 14
“However, TLS can occur spontaneously and with other tumor types with high proliferative rates, large tumor burden, or high sensitivity to cytotoxic therapy [11].”
BackgroundKondo, M., Hotta, Y., Yamauchi, K., Sanagawa, A., Komatsu, H., Iida, S., & Kimura, K. (2020) · BMC Cancer · doi:10.1186/s12885-020-07592-9 · Cited by 14
Kidney and Urinary Tract Involvement in Chronic Myelomonocytic Leukemia
Attieh, R. M., Begum, F., Chitty, D. W., Izzedine, H., & Jhaveri, K. D. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100769 · Cited by 13
Interdisciplinary Management of Acute Leukemia Across the Continuum of Care
Kurtin, S. E. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.150953 · Cited by 13
Fu, Z., Zhou, J., Chen, R., Jin, Y.-H., Ni, T., Qian, L.-B., & Xiao, C. (2020) · Oncology Letters · doi:10.3892/ol.2020.11897 · Cited by 13
Anderson, A., Shoulders, L., James, V., Ashcraft, E., Cheng, C., Ribeiro, R. C., & Elbahlawan, L. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1234677 · Cited by 13
“Duration of CKRT (days) 2 (1-7) TLS, tumor lysis syndrome; CKRT, continuous kidney replacement therapy; ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; BUN, blood urea nitrogen; Cr, creatinine; WBC, white blood cell count; LDH, lactate dehydrogenase; BSA, base surface area; ICU, intensive care uni…”
BackgroundYang, Y., Luo, K., & Xu, G. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110311 · Cited by 13
Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma ☆
Imam, S. Z., Zahid, M. F., & Maqbool, M. A. (2018) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2018.03.004 · Cited by 13
Disorders of Divalent Ions (Magnesium, Calcium, and Phosphorous) in Patients With Cancer
Rosner, M. H., & Renaghan, A. D. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.005 · Cited by 13
Gremke, N., Griewing, S., Kostev, K., Wagner, U. A. G., & Kalder, M. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06944-w · Cited by 13
“1 3 patients diagnosed with cancer prior to the index date were excluded since hyperuricemia (due to increased urate overproduction) can occur in patients with disorders involving high cell turnover such as advanced tumor diseases or highly proliferative myeloproliferative disorders [49, 50].”
BackgroundBaudon, C., Duhoux, F. P., Sinapi, I., & Canon, J.-L. (2016) · Journal of Medical Case Reports · doi:10.1186/s13256-016-0969-5 · Cited by 13
“TLS was previously well described in hematologic malignancies, but as treatments become more efficient, it is becoming increasingly frequent in solid tumors, which previously had been rarely associated with this complication [12].”
BackgroundIdentification of Children with Acute Lymphoblastic Leukemia at Low Risk for Tumor Lysis Syndrome
Gh.R., B., & Yazdi, E. (2015) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000318 · Cited by 13
“So earlier recognition and appropriate treatment is crucial [5,11].”
BackgroundTumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature
Catania, V. E., Vecchio, M. M., Malaguarnera, M., Madeddu, R., Malaguarnera, G., & Latteri, S. (2017) · Journal of Medical Case Reports · doi:10.1186/s13256-017-1241-3 · Cited by 13
“Tumor lysis syndrome (TLS) is one of the major oncological emergencies; disruption is caused by massive tumor cell lysis in which the contents of the lysed tumor cells are released into the bloodstream [1].”
BackgroundMyint, P. T., Butt, H. W., Alrifai, T., & Marin, C. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/6375693 · Cited by 13
Ye, Z., Palazzo, J., Lin, L., Lai, Y., Guiles, F., Myers, R. E., Han, J., Xing, J., & Yang, H. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12237 · Cited by 13
Tumour lysis syndrome in a patient with undifferentiated endometrial stromal sarcoma
Ahmed, Z. S., Barefah, A., Wasi, P., Jones, G. L., & Ramsay, J. A. (2019) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2019.02.006 · Cited by 12
“Symptomatic hyperkalemia and hypocalcaemia should be treated and there should be a low threshold for initiating renal replacement therapy (Howard et al., 2011; Davidson et al., 2004).”
BackgroundGangani, K., Fong, H. K., Faisaluddin, M., Lodhi, M. U., Manaktala, P. S., Sadolikar, A., Shah, V. P., Gandhi, Z., Hassan, F. A., Savani, S., et al. (2020) · Journal of Arrhythmia · doi:10.1002/joa3.12482 · Cited by 12
Shafie, M., Teymour, A., Parsa, S., Sadeghian, A., & Jalalabadi, N. Z. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03263-4 · Cited by 12
“It is rarely reported in solid tumors and may occur occasionally in solid tumors with a massive burden after receiving treatment [2].”
BackgroundArad‐Cohen, N., Zeller, B., Abrahamsson, J., Navarro, J. M. F., Cheuk, D. K., Palmu, S. A., Costa, V., Moerloose, B. D., Hasle, H., Jahnukainen, K., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2131544 · Cited by 12
“Together, these mechanisms result in renal failure leading to acidosis, which worsens electrolyte disturbances that may become life-threatening [21].”
Backgroundvan Mourik, N., Oomen, J., van Vught, L. A., Biemond, B. J., van den Bergh, W. M., Blijlevens, N. M. A., Vlaar, A. P. J., & Müller, M. C. A. (2023) · Intensive and Critical Care Nursing · doi:10.1016/j.iccn.2023.103486 · Cited by 12
Pro-inflammatory diets promote the formation of hyperuricemia
Liu, X., Chen, T., Gao, T., Shi, K.-Q., Yin, F.-Q., Yu, Y.-X., & Zhang, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398917 · Cited by 12
“Previous studies had shown that high purine diet, excessive alcohol consumption, increased purine metabolism, and tumor lysis syndrome (16) can lead to increased uric acid production.”
BackgroundPhilips, A. O., Radhakrishnan, V. S., Ganesan, P., Ganesan, T. S., Ramamurthy, J., Dhanushkodi, M., & Sagar, T. G. (2018) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-018-0938-9 · Cited by 12
Comparison of fixed versus traditional weight‐based dosing of rasburicase in a pediatric population
Savva, D. A., Herrera, N. A., & Rohatgi, R. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27236 · Cited by 12
“Females (# of patients) 4–11 years old, mean± SD (6) 5,306± 2,626 (3) 3,754± 0 0.”
Aspirasi Benda Asing pada Anak
Sugandha, P. U. (2018) · Cermin Dunia Kedokteran · doi:10.55175/cdk.v45i2.826 · Cited by 12
Hurdles for the Wide Implementation of Photoimmunotherapy
Matsuoka, K., Sato, M., & Sato, K. (2021) · Immunotherapy · doi:10.2217/imt-2021-0241 · Cited by 12
Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic Small Cell Carcinoma of the Lung
Padhi, P., & Singh, S. (2012) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000133 · Cited by 12
“As she had two of the metabolic derangements and acute kidney injury she had clinical tumor lysis syndrome [24].”
BackgroundZhou, J. (2014) · Journal of Clinical Case Reports · doi:10.4172/2165-7920.1000361 · Cited by 12
“This strategy, in cases of advanced B-cell non-Hodgkin’s lymphoma or Burkitt’s leukemia, has involved treatment with low-dose cyclophosphamide, vincristine, and prednisone for a week before the start of intensive chemotherapy [15].”
Yun, S., Walker, C. N., Vincelette, N. D., & Anwer, F. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-205044 · Cited by 12
Spontaneous tumor lysis syndrome in small cell lung cancer
Dean, R. K., Subedi, R., & Lee, M. (2017) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2017.1391042 · Cited by 12
“Despite being less commonly seen, TLS from solid tumors appears to carry a higher mortality rate than TLS in hematologic malignancies, with the mortality reported as high as 40%.(2,9) There is no evidence comparing mortality rates of spontaneous TLS in solid tumors due to its relative dearth in the literature.”
BackgroundMethodInfluentialBakker, R. C., de Roos, R., Ververs, T. F., Lam, M. G. E. H., van der Lee, M. K., Zonnenberg, B. A., & Krijger, G. C. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.03.001 · Cited by 12
“Other speculations for retention in the liver in such cases are decreased blood flow after embolization and high local concentrations of phosphates in the tumour regions due to necrosis [34].”
BackgroundNephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies
Wen, X., & Xu, G. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s465679 · Cited by 11
“Severity”
Yarandi, N., & Shirali, A. C. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.03.007 · Cited by 11
Iqbal, M., Mukhamedshin, A., Lezzar, D. L., Abhishek, K., McLennan, A., Lam, F. W., & Shevkoplyas, S. S. (2023) · Blood transfusion · doi:10.2450/bloodtransfus.506 · Cited by 11
Vega, M. W., Vuong, K. T., Chmielewski, J., Gollins, L. A., Slagle, C. L., Srivaths, P. R., & Akcan‐Arikan, A. (2023) · Nutrition in Clinical Practice · doi:10.1002/ncp.11048 · Cited by 11
Anaphylactic reactions to biological drugs
Matucci, A., Vultaggio, A., Nencini, F., & Maggi, E. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000666 · Cited by 11
“It is important to distinguish CRSs from other adverse events occurring during biological agent treatment such as tumor lysis syndrome clinically characterized by symptoms, such as fever, acute renal failure, cardiac arrhythmia, and seizures [40].”
BackgroundWang, Y., Lu, J., Huang, Z., Qian, M., Zhang, Q., & Feng, J. (2021) · Process Biochemistry · doi:10.1016/j.procbio.2021.01.026 · Cited by 11
Taniguchi, S., Yamauchi, T., Choi, I., Fukuhara, N., Potluri, J., Salem, A. H., Hong, W., Honda, H., Nishimura, Y., Okubo, S., et al. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab018 · Cited by 11
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
Yano, S., Kawaoka, T., Johira, Y., Miura, R., Kosaka, M., Shirane, Y., Murakami, S., Amioka, K., Naruto, K., Ando, Y., et al. (2021) · Medicine · doi:10.1097/md.0000000000027576 · Cited by 11
“Although this case did not meet the diagnostic criteria for TLS,([4]) the presence of signs of tumor necrosis on CT and the fact that the patient improved without steroids suggests it is likely that the condition was similar to TLS.”
Rogers, K. A., Lu, X., Émond, B., Côté‐Sergent, A., Kinkead, F., Lafeuille, M., Lefèbvre, P., & Huang, Q. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.22075 · Cited by 11
Ichaï, C., Vinsonneau, C., Souweine, B., Armando, F., Canet, E., Clec’h, C., Constantin, J., Darmon, M., Duranteau, J., Gaillot, T., et al. (2016) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2016.04.001 · Cited by 11
Agarwala, R., Batta, A., Suryadevera, V., Kumar, V., Sharma, V., & Rana, S. S. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.09.003 · Cited by 11
Low-dose Rasburicase in Hematologic Malignancies
Jayabose, S., Kumar, V., Dhanabalan, R., Rajan, P. T., Rathnam, K., & Viswanathan, T. K. (2014) · The Indian Journal of Pediatrics · doi:10.1007/s12098-014-1606-1 · Cited by 11
Imaging features of haematological malignancies of kidneys
Sandrasegaran, K., Menias, C. O., Verma, S. K., Abdelbaki, A., Shaaban, A. M., & Elsayes, K. M. (2015) · Clinical Radiology · doi:10.1016/j.crad.2015.11.007 · Cited by 11
Radiation-Induced Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia
Alkan, A., Kütük, T., Karcı, E., Yaşar, A., Hiçsönmez, A., & Utkan, G. (2016) · Turkish Journal of Hematology · doi:10.4274/tjh.2015.0259 · Cited by 11
“Laboratory TLS is defined as the imbalance of two or more electrolytes (hypocalcemia, hyperuricemia, hyperphosphatemia, hyperkalemia), whereas clinical TLS is defined as laboratory TLS plus one clinical finding (increased creatinine, arrhythmia/sudden death, seizure) [4,5,6,7].”
BackgroundPrincipaux troubles hydro-électrolytiques chez le patient de cancérologie
Saillant, A., Try, M., Laparra, A., Lecoq, A.-L., & Zaidan, M. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.04.014 · Cited by 10
Condoluci, A., Romano, I. J., Dietrich, D., Pini, K., Stüssi, G., Müller, G., Cantoni, N., Cathomas, R. L., Mey, U., Widmer, A., et al. (2025) · Blood · doi:10.1182/blood.2024026879 · Cited by 10
Brinton, T., Yousuf, T., Steinecker, G., & Rydel, J. J. (2015) · PubMed · Cited by 10
Endocrine and Metabolic Emergencies
Yeung, S. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-26387-8_21 · Cited by 10
Dudala, S. S., Venkateswarulu, T. C., Narayana, A. V., Krupanidhi, S., & Dulla, J. B. (2023) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2023.102649 · Cited by 10
Calvache, E. T., Calvache, A. D. T., & Weber, C. S. (2023) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2023.02.005 · Cited by 10
Gallego-Valle, J., Pérez-Fernández, V. A., Magallares, J. R., Gil-Manso, S., Castellà, M., González‐Navarro, E. A., Correa‐Rocha, R., Juan, M., & Pion, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448752 · Cited by 10
“Additionally, CAR-T therapy is currently only feasible for certain types of cancer and has shown limited ef fi ciency against solid tumors, restricting its availability to a broader patient population (2, 11 – 13).”
Management of Oncologic Emergencies
Freedman, J. L., & Rheingold, S. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801368-7.00032-6 · Cited by 10
Brunnhoelzl, D., Weed, M. R., Trepet, R., & Wang, J. (2017) · Archives in Cancer Research · doi:10.21767/2254-6081.1000127 · Cited by 10
“Tumor lysis syndrome (TLS) is a potential complication in cancer therapy, which is caused by the sudden, rapid death of cells, occurs much more commonly in patients with aggressive non-Hodgkin’s lymphomas, such as Burkitt’s lymphoma, and leukemias, in response to cancer therapies [1-9].”
BackgroundPromises and pitfalls of targeted agents in chronic lymphocytic leukemia
Lew, T. E., Anderson, M. A., & Seymour, J. F. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.108 · Cited by 10
“reported a detailed analysis of 166 patients managed with this step-wise dose escalation protocol and risk adapted TLS prevention and management strategy as per manufacturer guidelines([58]), identifying five cases of investigator assessed TLS, although none met formal Howard laboratory or clinical criteria([59]).”
MethodChimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies
Zhou, H., Yang, M., Cui, L., & Jiang, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107072 · Cited by 10
Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System
Cohen, P. R., Prieto, V. G., & Kurzrock, R. (2021) · Cureus · doi:10.7759/cureus.13816 · Cited by 10
“In addition, dehydration and diminished kidney function (which may be more common in older individuals) have also been associated with an increased risk of systemic tumor lysis syndrome developing after malignancy-directed therapy has been initiated [1,2,9,10].”
BackgroundInfluentialYeung, S. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-67123-5_29 · Cited by 10
Yaman, S., Başçı, S., Turan, G., Ulu, B. U., Yiğenoğlu, T. N., Dal, M. S., Çakar, M. K., & Altuntaş, F. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.08.009 · Cited by 10
Kala, J., & Finkel, K. W. (2021) · Critical Care Clinics · doi:10.1016/j.ccc.2020.11.004 · Cited by 10
Outpatient initiation of venetoclax in patients with acute myeloid leukemia
Palmer, S., Patel, A. A., Wang, C., Patel, B. A., Zeidner, J. F., Foster, M. C., Muluneh, B., & Buhlinger, K. M. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221142872 · Cited by 10
Xia, S., Ma, J., Raschi, E., Ma, R., Zhang, B., Guo, L., Noguchi, Y., Sarangdhar, M., Gong, H., & Yan, M. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01308-0 · Cited by 10
“Previous reviews [6–8] showed that TLS may occur with CD20 mAbs.”
BackgroundMethodManagement of Tumor Lysis Syndrome in Patients With Multiple Myeloma During Bortezomib Treatment
Wang, L., Jian, Y., Yang, G., Gao, W. X., Wu, Y., & Zuo, L. (2015) · Clinical journal of oncology nursing · doi:10.1188/15.cjon.e4-e7 · Cited by 10
“These metabolic complications predispose patients with cancer to various clinical toxicities, including renal insufficiency, cardiac arrhythmias, seizures, neurologic complications, and, potentially, sudden death (Cairo & Bishop, 2004; Mathisen, 2011).”
Tragiannidis, A., Pana, Z. D., Papageorgiou, T., Hatzipantelis, E., Hatzistilianou, M. N., & Athanassiadou, F. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-407 · Cited by 10
“Tumor lysis syndrome (TLS) is rarely reported after initiation of effective chemotherapy as a complication of transient myeloproliferative disorder [7].”
BackgroundSevere acute kidney injury as presentation of Burkitt's lymphoma
ter Haar, E., Labarque, V., Tousseyn, T., & Mekahli, D. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-214780 · Cited by 10
Spontaneous Tumor Lysis Syndrome due to Uterine Leiomyosarcoma with Lung Metastases
Alaigh, V., & Datta, D. (2017) · Case Reports in Critical Care · doi:10.1155/2017/4141287 · Cited by 10
“A patient who does not respond to these measures may need renal replacement therapy to manage electrolyte abnormalities and renal failure [3, 5].”
BackgroundInfluentialKearney, M., Chen, E. Y.-S., Stenzel, P., Corless, C. L., DeLoughery, T. G., Zivney, M., & Lopez, C. D. (2018) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-018-0102-7 · Cited by 10
Single 6-mg dose of rasburicase: The experience in a large academic medical center
Nauffal, M., Redd, R. A., Ni, J., Stone, R. M., DeAngelo, D. J., & McDonnell, A. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218791333 · Cited by 10
Parsi, M., Rai, M., & Clay, C. (2019) · Cureus · doi:10.7759/cureus.6186 · Cited by 10
Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia
Zhang, B., Lee, A. I., & Podoltsev, N. A. (2014) · Oxford Medical Case Reports · doi:10.1093/omcr/omu053 · Cited by 10
“TLS is typically associated with rapidly proliferating lymphoid neoplasms such as high-grade non-Hodgkin lymphomas (particularly Burkitt lymphoma) and acute leukemias with white blood cell (WBC) counts of over 100 000/ml, although uncommon it may also be seen in chronic lymphocytic leukemia (CLL) treated with chemoimm…”
BackgroundUrine Xanthine Crystals in Tumor Lysis Syndrome
Omokawa, A., Oguma, M., Ueki, S., Saga, T., & Hirokawa, M. (2018) · Urology · doi:10.1016/j.urology.2018.07.009 · Cited by 10
Cho, W. H., Kim, H., Yoo, S., Lee, S. M., Kim, T. J., & Lee, J. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00733-x · Cited by 9
“Rasburicase is primarily used to manage acute hyperuricemia in patients with TLS, whereas pegloticase, a PEGylated version of uricase, is used to treat chronic refractory gout (Howard et al. 2011; Yang et al. 2012).”
Saiyin, T., Christou, G., Sabloff, M., Crosbie, T., Nguyen-Tham, K.-M., & Fulcher, J. (2025) · Current Oncology · doi:10.3390/curroncol32040213 · Cited by 9
“…normal laboratory reference range was questioned by Howard and colleagues, and in their revision of the diagnostic criteria for TLS, increases in potassium, phosphate, and uric acid of 25% from baseline are only considered to be of clinical value when the baseline value is higher than normal [11].”
InfluentialDavids, M. S., Chanan-Khan, A. A., Ailawadhi, S., Ivanov, V., Usenko, G., Nogaieva, L., Kryachock, I., Muzhychuk, I., Perekhrestenko, T., Kyselova, O., et al. (2025) · Med · doi:10.1016/j.medj.2025.100885 · Cited by 9
Tumor lysis syndrome in a patient with metastatic melanoma treated with nivolumab
Sugimoto, S., Terashima, T., Yamashita, T., Iida, N., Kitahara, M., Hodo, Y., Shimakami, T., Takatori, H., Arai, K., Kawaguchi, K., et al. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01164-x · Cited by 9
Rasburicase induced methemoglobinemia: A systematic review of descriptive studies
Hanumanthaiah, V. B., Zuber, M., Taj, S., Venkataraman, R., Kumar, B. S., & Jabeen, N. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221075239 · Cited by 9
“most common oncology emergency, and morbidity and mortality are high without timely detection and early clinical intervention.(1) It is also an anticipated complication of hematologic malignancies from the initiation of cytotoxic chemotherapy but can occur spontaneously as well.”
BackgroundSpontaneous tumor lysis syndrome (STLS) during biopsy for burkitt lymphoma: a case report
Pan, S., Shen, Q., Zhou, J., & Li, T. (2024) · BMC Pediatrics · doi:10.1186/s12887-024-04679-1 · Cited by 9
“Hyperuricemia is one of the major risk factors associated with TLS, as it can cause AKI, which in turn increases the risk of mortality [2, 18].”
BackgroundTumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era
Toda, Y., Ashizawa, M., Murahashi, R., Nakashima, H., Ikeda, T., Kawaguchi, S., Nagayama, T., Umino, K., Minakata, D., Morita, K., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03752-w · Cited by 9
“Tumor lysis syndrome (TLS) leads to heart failure, arrhythmias, seizures, muscle cramps, tetany, syncope, and sudden death, and is, therefore, considered an “oncologic emer-gency” [1, 2].”
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen
Rowe, M., Babushok, D. V., Carroll, M. P., Carulli, A., Frey, N. V., Gill, S. I., Hexner, E. O., Hirsh, R. L., Hossain, N. M., Lai, C., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14371 · Cited by 9
“There are two main sets of criteria used to diagnose TLS: Cairo Bishop criteria and Howard criteria (Table 1) [6, 7].”
Zhao, J., Li, X., Sun, X., Xiao, R., Xue, J., Sui, K., & Liu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533700 · Cited by 9
“Tumor lysis syndrome may also increase vascular permeability, facilitating bacterial entry into liver tissue (27).”
Metadata
- Authors
- Howard, S. C., Jones, D. P., & Pui, C.-H.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-12
- Volume
- 364
- Issue
- 19
- Pages
- 1844-1854
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3437249
- OpenAlex
- W2122479144
- Cited by
- 1,044
- References
- 58
- Citations by year
- 2026: 71 · 2025: 67 · 2024: 86 · 2023: 71 · 2022: 69 · 2021: 81 · 2020: 89 · 2019: 154 · 2018: 60 · 2017: 53 · 2016: 49 · 2015: 57 · 2014: 47 · 2013: 49 · 2012: 31
- FWCI
- 36.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA21765, P30CA021765)
- National Institute of General Medical Sciences (U01GM92666, U01GM092666)
- Topics
- Health Sciences › Medicine › Hematology › Methemoglobinemia and Tumor Lysis Syndrome
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
- Keywords
- tumor lysis syndrome, hematologic malignancies, risk assessment, prophylaxis, treatment, pediatric oncology, emergency management
- MeSH terms
- Child, Humans, Male, Tumor Lysis Syndrome, Risk Assessment, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.